Verification of the preventive effect for vincristin-induced peripheral neuropathy by frozen gloves and socks

Verification of the preventive effect for vincristin-induced peripheral neuropathy by frozen gloves and socks - Verification of the preventive effect for vincristin-induced peripheral neuropathy by frozen gloves and socks

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017815

Enrollment

Registered

2015-06-08

Start date

2015-06-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

All patients wear frozen glove and socks on either side of hand and foot.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Diagnosed as histologically malignant lymphoma receiving (R-) CHOP therapy or (R-) CVP therapy (vincristin administration). 2) Diagnosed as histologically Ewing sarcoma receiving VDC therapy or VAC therapy (vincristin administration). 3) Diagnosed as histologically rhabdomyosarcoma receiving radiation therapy combination VAC (2200) or VAC (1200) therapy or radiation 4) Patients planned to receive chemotherapy in the age over 15 years old of hospitalization or outpatient chemotherapy room. 5) Cases to have agreed to enter this study as participants from the description document.

Exclusion criteria

Exclusion criteria: 1) Drug allergy that might interfere with this drug, patients with cold allergy and its history. 2)Patients with any of the grade two or more of peripheral neuropathy or limb edema in the registration time. 3)Patients with metastatic tumor found in (sub)cutaneous lesion. 4) Patients with Raynaud's symptoms, peripheral arterial ischemia symptoms, hand-foot syndrome, or injury in the hands or feet, and patients the doctor has determined inadequate for this study. 5) Patients with demyelinating Charcot-Marie-Tooth disease. 6) Patients with pregnancy or breast-feeding.

Design outcomes

Primary

Measure	Time frame
Incidence of chemotherapy-induced peripheral neuropathy assessed at each cycle	—

Secondary

Measure	Time frame
FACT/GOG-NTx(patient questionnaire) Tolerability of frozen gloves and socks Skin toxicity	—

Countries

Japan

Contacts

Public ContactMayumi Haruta

Nagoya City University Hospital Division of Chemotherapy

kbkyw108@ybb.ne.jp052-851-5511(7428)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026